Bellerophon Therapeutics, which is developing drug-device therapies for pulmonary and cardiac diseases, raised $60 million by offering 5 million shares at $12, below the range of $14 to $16. The company had originally planned to sell 4 million shares. Bellerophon Therapeutics plans to list on the NASDAQ under the symbol BLPH. Leerink Partners and Cowen & Company acted as lead managers on the deal.
